Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD123 targeted CAR-NK cells
- Development stage
- Phase 2
- Lead developer
- Chongqing Precision Biotech Co., Ltd
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD123 targeted CAR-NK cells are genetically engineered natural killer (NK) cell therapies designed to express a chimeric antigen receptor (CAR) that specifically targets the interleukin-3 receptor alpha chain (CD123), which is overexpressed on leukemic stem cells and myeloid blasts in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The therapy aims to enhance NK-cell antitumor effects while reducing toxicity compared to other cellular therapies. Preclinical studies have demonstrated potent antigen-dependent activation and cytotoxicity against AML both *in vitro* and *in vivo*. Clinical trials are ongoing for relapsed/refractory AML and BPDCN[1][2][4][5].
- Other names
- anti-CD123-CAR-NK-92 cellsanti-CD-123-CAR-NK-92 cellsanti-CD 123-CAR-NK-92 cellstargeting CD123 chimeric antigen receptor natural killer cells
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on CD123 targeted CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD123 targeted CAR-NK cells.